DPC-423 is a factor Xa inhibitor potentially for the treatment of thrombosis. In vivo and in vitro studies with the synthetic oxime intermediate from DPC-423 showed an adduct identical to the one extracted from the bile of rats dosed with DPC-423. This supported the intermediacy of an aldoxime as a precursor to the GSH adducts. It is postulated that the benzylamine moiety of DPC-423 (and its analogues) is oxidized to a hydroxylamine, which is subsequently converted to a nitroso intermediate. Subsequent rearrangement of the nitroso leads to an aldoxime which in turn is metabolized by P450 to a reactive intermediate. The formation of oxime from DPC-423 (and its analogues) was found to be mediated by rat CYP 3A1/2, which were also responsible for converting the oxime to the GSH trappable reactive intermediate. References: Taglialatela M. DPC-423 Bristol-Myers Squibb. Curr Opin Investig Drugs. 2002 Feb;3(2):252-4. Review. PubMed PMID: 12020055.

纯度：≥98%

CAS：292135-59-2